Sanofi-Synthelabo chief executive Jean-Francois Dehecq is preparing his company to merge with larger Franco-German neighbours Aventis to create the world's …
Velcade, the first in a new class of cancer drugs has been launched in the UK as a third line …
Brussels-based UCB is to buy the UK's number one biotech company Celltech for around $1.5 billion, creating the world's fifth …
AstraZeneca has written to healthcare professionals in the UK after a small number of patients reported serious side effects after …
A recent report by the Equal Opportunity Commission (EOC), Promoting Gender Equality in Health, has highlighted a significant omission which …
GlaxoSmithKline has paid $129 million to a small US biotech company for a three-year worldwide licensing option on all the …
Revenues from the European biotech sector have fallen back for the first time in 2003, as many companies across the …
The latest addition to AstraZeneca’s oncology franchise, breast cancer drug Faslodex has been launched in the UK.Licensed for the treatment …
Bristol-Myers Squibb and Solvay are to collaborate on the development and marketing of a novel phase I compound for the …
The industry and NICE have reached agreement on how the cost and clinical effectiveness body can meet demands for transparency …
Competitors in one of the industry's fastest growing markets, the TNF-blocker class of rheumatoid arthritis drugs, have gained extensions to …
New legislation will be introduced to combat animal rights extremists' violence against those involved in using animals in medical research.But …
Biota, the Australian biotech company that discovered Relenza, is taking GlaxoSmithKline to court, alleging that it failed to properly launch …
A phase III trial of a drug to treat ovarian cancer has disappointed and is likely to be dropped, co-developers …
Aventis has dropped its long-running opposition to a takeover bid by French compatriots Sanofi-Synthlabo after the offer to its shareholders …
The government is shortly to announce the approval of the world's first over-the-counter statin, Zocor Heart Pro, but is unlikely …